NeoHack Patented Formulations Mobilize Endogenous Stem Cells
Doctor Brown's Blog
The Body's Own Stem Cells can now be mobilized to address Alzheimer's disease
Stem Cells are nature's healing tools, mobilizing endogenous stem cells now possible
with NeoHack’s recent patent
January 14, 2026
As of 2026, regenerative medicine for Alzheimer’s disease (AD) has shifted toward stimulating the brain’s innate repair mechanisms. Research into bioactive compounds like β-caryophyllene, dexpanthenol, and spilanthol highlights their potential to activate endogenous neural stem cells (NSCs), offering a multi-faceted approach to restoring cognitive function and mitigating neurodegeneration. See our 2025 patents at https://neohacksciences.com/newest-patents .
Spilanthol: The Emerging Stem Cell Secretagogue* (see definition below)
Spilanthol, an alkylamide derived from Acmella oleracea (the "toothache plant"), is increasingly recognized for its ability to penetrate the blood-brain barrier and modulate neural signaling.
- Stem Cell Recruitment: Recent findings suggest spilanthol acts as a chemical "secretagogue," triggering the release of endogenous growth factors that recruit NSCs to damaged neural tissues.
- Anti-Inflammatory Synergy: Like aromatic-turmerone, spilanthol may inhibit p38 MAP kinase activity, which prevents the premature differentiation of NSCs into glia (scar tissue) and instead favors their development into functional neurons.
- Cognitive Enhancement: By dampening microglial overactivation, spilanthol protects the newly generated endogenous cells from the toxic inflammatory milieu characteristic of the AD brain.
Caryophyllene: A Cannabinoid-Like Neuroprotector
Beta-caryophyllene (BCP) is a dietary sesquiterpene found in black pepper, cloves, and rosemary. It acts as a selective agonist for the cannabinoid receptor type 2 (CB2), which is prominently expressed in the central nervous system during neuroinflammatory states.
- Endogenous Stem Cell Activation: Studies in late 2025 demonstrate that BCP facilitates the proliferation of endogenous NSCs in the hippocampus, a primary site of AD-related atrophy.
- Mechanisms of Action: BCP enhances the expression of brain-derived neurotrophic factor (BDNF), a critical signal for stem cell differentiation and synaptic plasticity.
- AD Pathology Mitigation: Preclinical models show BCP reduces amyloid-beta (Aβ) plaque accumulation and inhibits neuroinflammatory pathways (JAK2/STAT3), which typically suppress the regenerative capacity of dormant stem cells.
Dexpanthenol: Cholinergic Support and Neurodegeneration
Dexpanthenol, a precursor to Vitamin B5 (pantothenic acid), is traditionally known for its wound-healing properties but has emerged as a potent neuroprotective agent in AD research.
- Cholinergic Restoration: It is essential for the synthesis of acetylcholine, the neurotransmitter most severely depleted in AD.
- Neurogenesis Promotion: By reducing oxidative stress and neuroinflammation, dexpanthenol creates a permissive environment for endogenous NSCs to thrive.
- Hippocampal Preservation: Research indicates that dexpanthenol prevents neuronal loss in the cornu ammonis (CA1 and CA3) regions, effectively reversing memory deficits in sporadic-AD models by supporting the survival of newly formed neurons.
Clinical Outlook in 2026
The integration of these ingredients represents a paradigm shift from "cell replacement" (transplantation) to "cell activation" (regeneration). In late 2025, phase 1 and 2 trials began exploring autologous stem cell approaches that utilize similar molecular pathways to stimulate dormant ventricular stem cells. While not yet a standalone "cure," the combination of BCP, dexpanthenol, and spilanthol offers a promising strategy to slow, and potentially reverse, the cognitive decline associated with Alzheimer's disease.
*A secretagogue is an agent that promotes the secretion of hormones, neurohormones, chemical neurotransmitters, enzymes, or other compounds synthesized and secreted by cells.
NeoHack Life Sciences senior managers may be reached via the emails below for information regarding licensing rights for 20 of its patented claims:
CEO, Ron Butler email: rb@neohacksciences.com
CSO, Dr. Dale Brown email: db@neohacksciences.comAnyone will tell you that the science of "pain management" in the last two decades has been fraught with miscalculations, missteps and outright abuses. It has largely produced only what it says: management. Believing that management was not enough, NeoHack set out to learn new sources of relief and better systemic applications from the best teacher of all -- nature. Read on to learn what we found.